Haemoptysis as symptom of SARS-CoV-2 infection – case study
More details
Hide details
Studenckie Koło Naukowe przy Katedrze i Klinice Chorób Płuc i Gruźlicy, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Zakład Radiologii Lekarskiej i Radiodiagnostyki, Samodzielny Publiczny Szpital Kliniczny nr 1 im. prof. Stanisława Szyszko w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Katedra i Klinika Chorób Płuc i Gruźlicy, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Corresponding author
Dagmara Galle   

Studenckie Koło Naukowe przy Katedrze i Klinice Chorób Płuc i Gruźlicy, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Ks. Koziołka 1, 41-803 Zabrze
Ann. Acad. Med. Siles. 2022;76:31-35
For over two years, doctors and scientists have been dealing with the issue of COVID-19, caused by infection with the new coronavirus SARS-CoV-2. The various signs and complications of COVID-19 are still being identified. In this article, we present the case of a 61-year old woman with a history of chronic bronchitis, who was admitted to the Pulmonology Department Prof. Stanisław Szyszko Independent Public Clinical Hospital No 1 in Zabrze for haemoptysis after having recovered from COVID-19. After clinical examination, laboratory investigation, and imaging scans, we considered that the haemoptysis was most likely caused by respiratory tract inflammation. The patient was treated with antibiotics, glucocorticosteroids, as well as antihaemorrhagic and antitussive drugs. During the patient’s hospital stay, the haemoptysis gradually disappeared and the patient was discharged home in a very good clinical condition.
None declared
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506, doi: 10.1016/S0140-6736(20)30183-5.
da Rosa Mesquita R., Francelino Silva Junior L.C., Santos Santana F.M., Farias de Oliveira T., Campos Alcântara R., Monteiro Arnozo G. et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien. Klin. Wochenschr. 2021; 133(7–8): 377–382, doi: 10.1007/s00508-020-01760-4.
Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382(18): 1708–1720, doi: 10.1056/NEJMoa2002032.
Shi F., Yu Q., Huang W., Tan C. 2019 Novel coronavirus (COVID-19) pneumonia with hemoptysis as the initial symptom: CT and clinical features. Korean J. Radiol. 2020; 21(5): 537–540, doi: 10.3348/kjr.2020.0181.
Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis [preprint]. medRxiv 2021; 2021.01.27.21250617, doi: 10.1101/2021.01.27.21250617.
Wang T.J., Chau B., Lui M., Lam G.T., Lin N., Humbert S. et al. Physical medicine and rehabilitation and pulmonary rehabilitation for COVID-19. Am. J. Phys. Med. Rehabil. 2020; 99(9): 769–774, doi: 10.1097/PHM.0000000000001505.
Grigoletto I., Cavalheri V., de Lima F.F., Ramos E.M.C. Recovery after COVID-19: The potential role of pulmonary rehabilitation. Braz. J. Phys. Ther. 2020; 24(6): 463–464, doi: 10.1016/j.bjpt.2020.07.002.
Earwood J.S., Thompson T.D. Hemoptysis: evaluation and management. Am. Fam. Physician. 2015; 91(4): 243–249.
Ittrich H., Bockhorn M., Klose H., Simon M. The diagnosis and treatment of hemoptysis. Dtsch. Arztebl. Int. 2017; 114(21): 371–381, doi: 10.3238/arztebl.2017.0371.
Liang W., Liang H., Ou L., Chen B., Chen A., Li C. et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern. Med. 2020; 180(8): 1081–1089, doi: 10.1001/jamainternmed.2020.2033.
Izcovich A., Ragusa M.A., Tortosa F., Lavena Marzio M.A., Agnoletti C., Bengolea A. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 2020; 15(11): e0241955, doi: 10.1371/journal.pone.0241955.
Ahmed O.F., Kakamad F.H., Hama Amin B.J., Abdullah B.A., Hassan M.N., Salih R.Q. et al. Post COVID-19 pulmonary complications; a single center experience. Ann. Med. Surg. (Lond.) 2021; 72: 103052, doi: 10.1016/j.amsu.2021.103052.
Han H., Yang L., Liu R., Liu F., Wu K.L., Li J. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. 2020; 58(7): 1116–1120, doi: 10.1515/cclm-2020-0188.
Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18(4): 844–847, doi: 10.1111/jth.14768.
Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020; 18(5): 1094–1099, doi: 10.1111/jth.14817.
Barek M.A., Aziz M.A., Islam M.S. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases. Heliyon 2020; 6(12): e05684, doi: 10.1016/j.heliyon.2020.e05684.
Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A.E. et al. COVID-19 and comorbidities: deleterious impact on infected patients. J. Infect. Public Health 2020; 13(12): 1833–1839, doi: 10.1016/j.jiph.2020.07.014.
Pruszczyk P., Torbicki A. Pulmonary embolism. In: R. Jaeschke, P. Gajewski, P.M. O’Byrne [ed.]. McMaster textbook of internal medicine 2019/20. Medycyna Praktyczna. Kraków 2019, p. 436–448.
Skornicz A., Madziarski M., Gajek A., Madziarska K. Zatorowość płucna – przegląd metod diagnostyki obrazowej. Folia Cardiol. 2018; 13(6): 517–525, doi: 10.5603/FC.a2018.0118.
Weekly epidemiological update on COVID-19. Ed. 69. World Health Organization [online], 7 December 2021. Available at: https://www.who.int/pu-blicati... [accessed on 25 April 2022].
Journals System - logo
Scroll to top